Tests GLP-1 drugs or nutrition counseling in psoriatic arthritis with obesity and diabetes
Compares GLP-1 medicines with nutrition counseling in adults with psoriatic arthritis, obesity and diabetes.
Plain-language title generated from the registry record
Registry title: Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial
Key facts
- Where
- Milwaukee, United StatesSee the site
- Phase
- Phase 4
Where in United States
- Medical College of Wisconsin/Froedtert HosptialMilwaukee, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Medical College of Wisconsin
- Trial code
- NCT07111494
- Record updated
- 5 November 2026
- Original description
Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects the joints but can also have an effect on multiple parts of the body. This study will assess if the effectiveness of Glucagon-like peptide-1 (GLP-1) medications used to treat type 2-diabetes and weight management, or nutrition counseling can better treat individuals with Psoriatic Arthritis who are also needing treatment for obesity and type 2 diabetes.Read full original descriptionShow less
Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial
Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects the joints but can also have an effect on multiple parts of the body. This study will assess if the effectiveness of Glucagon-like peptide-1 (GLP-1) medications used to treat type 2-diabetes and weight management, or nutrition counseling can better treat individuals with Psoriatic Arthritis who are also needing treatment for obesity and type 2 diabetes.
The main objectives it aims to answer are:
To assess disease outcomes of PsA patients undergoing treatment for concomitant obesity and type 2 diabetes with GLP-1 analogs vs nutrition counseling.
To assess effectiveness as measured by clinical and patient reported outcome measures in patients treated with GLP-1 and nutrition counseling.
Participants will be randomized to receive a GLP-1 or nutrition counseling. Participants will be asked to come to the study center at most four times during a 24-week period. During this time participants will be asked to fill out questionnaires, receive a physical exam, and have their blood drawn.
Inclusion: Adult patients (age 18 and older) who present to rheumatology clinic; Participants must be able to read, understand, and provide documented informed consent as approved by the Institutional Review Board (IRB); Meet the Classification of Psoriatic Arthritis (CASPAR) criteria for PsA; Participants must have a Body Mass Index (BMI) of 30kg/m\^2; Participants must be treated for PsA in accordance with guidelines; Have not achieved MDA in PsA patients; Have a minimum TJC > 1 and SJC > at baseline; Eligible for GLP-1 agonist treatment in accordance with Food Drug Administration (FDA) labeling as determined by the investigator.
Exclusion: Any prior use of GLP-1 agonists; Patients with hemoglobin A1c (HbA1c) > 10 at baseline; Inability to provide informed consent; Current participation in another PsA study; Treatment initiation by GLP-1 agonists contraindicated by FDA.